Duration and impact of adverse events with esketamine nasal spray and quetiapine extended release in the ESCAPE-TRD phase IIIb trial — Eduard Vieta (2023) | RDL Network
Andreas Reif, Bernhard T. Baune, Jozefien Buyze, Anthony J. Cleare, Sunny Johnson, Yerkebulan Kambarov, Nigel Olisa, Falk Schuster, C. von Holt, Tamara Werner‐Kiechle, Eduard Vieta
Roger S. McIntyre, István Bitter, Jozefien Buyze, Andrea Fagiolini, Yordan Godinov, Philip Gorwood, Tetsuro Ito, Albino J. Oliveira‐Maia, Eduard Vieta, Tamara Werner‐Kiechle, Allan H. Young, Andreas Reif
Eduard Vieta, N. Ahmed, C. Arango, Anthony J. Cleare, Koen Demyttenaere, Markus Dold, Tetsuro Ito, Y. Kambarov, Stephanie Krüger, Pierre‐Michel Llorca, Roger S. McIntyre, Gabriele Sani, C. von Holt, B. Rive
Iría Grande, Flávio Kapczinski, Laura Stertz, Gabriela Delevati Colpo, Maurício Kunz, Keila M. Ceresér, Márcia Kauer-Sant’Anna, Benício N. Frey, Eduard Vieta, Pedro Vieira da Silva Magalhães
Discussion(0)
No comments yet. Be the first to comment.